Organogenesis EBITDA 2017-2024 | ORGO

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Revenue Gross Profit Operating Income EBITDA Net Income Shares Outstanding

Organogenesis ebitda from 2017 to 2024. Ebitda can be defined as earnings before interest, taxes, depreciation and amortization.

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Revenue Gross Profit Operating Income EBITDA Net Income Shares Outstanding

Organogenesis ebitda from 2017 to 2024. Ebitda can be defined as earnings before interest, taxes, depreciation and amortization.

Related Stocks
Company Name	Market Cap
Zoetis (ZTS)	$89B
Takeda Pharmaceutical (TAK)	$47.2B
Merck (MKGAF)	$23.7B
Astellas Pharma (ALPMY)	$22.1B
Summit Therapeutics (SMMT)	$17.8B
Sandoz Group AG (SDZNY)	$17.6B
United Therapeutics (UTHR)	$15.2B
Shionogi (SGIOY)	$13.1B
Neurocrine Biosciences (NBIX)	$12.1B
Catalent (CTLT)	$10.9B
Orion OYJ (ORINY)	$7.4B
Revolution Medicines (RVMD)	$7.4B
Jazz Pharmaceuticals (JAZZ)	$6.8B
Ionis Pharmaceuticals (IONS)	$6.2B
Hikma Pharmaceuticals Plc (HKMPF)	$5.7B
Madrigal Pharmaceuticals (MDGL)	$5.1B
Corcept Therapeutics (CORT)	$4.4B
Crinetics Pharmaceuticals (CRNX)	$4.2B
Dyne Therapeutics (DYN)	$3.4B
PTC Therapeutics (PTCT)	$2.7B
AMNEAL PHARMACEUTICALS, INC (AMRX)	$2.7B
Arrowhead Pharmaceuticals (ARWR)	$2.6B
Catalyst Pharmaceuticals (CPRX)	$2.4B
Soleno Therapeutics (SLNO)	$2.1B
Recursion Pharmaceuticals (RXRX)	$1.9B
Centessa Pharmaceuticals (CNTA)	$1.8B
BioCryst Pharmaceuticals (BCRX)	$1.6B
Xencor (XNCR)	$1.6B
Harrow (HROW)	$1.6B
Cassava Sciences (SAVA)	$1.5B